Lilly’s oral orforglipron readies for launch in catalyst-rich year for obesity

Wednesday’s highly anticipated FDA approval of Eli Lilly’s oral small molecule Foundayo for obesity clears the runway for the second oral GLP-1 receptor agonist to be launched. The approval, which follows Novo Nordisk’s January launch of oral peptide Wegovy, also marks at least the tenth obesity milestone reached in this year’s catalyst calendar.

Foundayo orforglipron from Eli Lilly and Co. (NYSE:LLY) is approved for adults with obesity or overweight adults with at least one weight-related co-morbidity, in combination with a reduced-calorie diet and increased physical activity. It is expected to launch this quarter...